Frazier Life Sciences IX L.P. 13D and 13G filings for Tarsus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-06 10:26 am Purchase | 2024-09-30 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Frazier Life Sciences IX L.P. | 1,587,527 4.200% | 170,370 (+12.02%) | Filing |
| 2022-01-28 2:09 pm Sale | 2021-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Frazier Life Sciences IX L.P. | 1,417,157 6.900% | -500,000 (-26.08%) | Filing |
| 2020-10-23 1:40 pm Purchase | 2020-10-20 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Frazier Life Sciences IX L.P. | 1,917,157 9.500% | 1,917,157 (New Position) | Filing |